Stopping vs. Continuing Aspirin before Coronary Artery Surgery

Area of Science:

• Cardiology
• Vascular Surgery
• Pharmacology

Background:

• Aspirin is widely used for cardiovascular disease prevention.
• Its use before coronary artery surgery carries potential bleeding risks.
• Evidence is lacking on whether to stop aspirin preoperatively for cardiac surgery.

Purpose of the Study:

• To evaluate the effect of preoperative aspirin on perioperative outcomes in patients undergoing coronary artery surgery.
• To determine if aspirin reduces or increases risks of death, thrombotic events, or bleeding.

Main Methods:

• A randomized, double-blind, placebo-controlled factorial trial.
• 2100 patients undergoing coronary artery surgery were randomized to aspirin (100 mg) or placebo preoperatively.
• The primary outcome was a composite of death and thrombotic complications within 30 days.

Main Results:

• No significant difference in the primary outcome (death or thrombotic complications) between aspirin and placebo groups (19.3% vs. 20.4%, P=0.55).
• Rates of major hemorrhage leading to reoperation were similar (1.8% vs. 2.1%, P=0.75).
• A trend towards increased cardiac tamponade in the aspirin group (1.1% vs. 0.4%, P=0.08) was observed.

Conclusions:

• Preoperative aspirin administration did not significantly reduce the risk of death or thrombotic complications in patients undergoing coronary artery surgery.
• Aspirin did not significantly increase the risk of bleeding complications compared to placebo.
• These findings suggest that continuing aspirin may be safe for patients undergoing coronary artery surgery.